Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Follow-Up Questions
Minerva Neurosciences Inc (NERV)의 PER은 얼마입니까?
Minerva Neurosciences Inc의 PER은 10.393입니다
Minerva Neurosciences Inc의 CEO는 누구입니까?
Dr. Remy Luthringer은 2014부터 회사에 합류한 Minerva Neurosciences Inc의 Executive Chairman of the Board of Directors입니다.
NERV 주식의 가격 성능은 어떻습니까?
NERV의 현재 가격은 $2.04이며, 전 거래일에 increased 0.58% 하였습니다.
Minerva Neurosciences Inc의 주요 사업 주제나 업종은 무엇입니까?
Minerva Neurosciences Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Minerva Neurosciences Inc의 시가총액은 얼마입니까?
Minerva Neurosciences Inc의 현재 시가총액은 $14.2M입니다
Minerva Neurosciences Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Minerva Neurosciences Inc에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 0명의 매수, 3명의 보유, 1명의 매도, 그리고 0명의 강력한 매도를 포함합니다
